Cancers that U.S. physicians believe the HPV vaccine prevents: Findings from a physician survey, 2009

Journal of Women's Health

Volumn 21, Issue 2, 2012, Pages 111-117

  Saraiya, Mona ^a   Rosser, Joelle I ^b   Cooper, Crystale Purvis ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Soltera Center for Cancer Prevention and Control   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; CANCER PREVENTION; GENERAL PRACTITIONER; GYNECOLOGIST; HEALTH SURVEY; HUMAN; MEDICAL SPECIALIST; OBSTETRICS; OROPHARYNX CANCER; PEDIATRICIAN; PHYSICIAN; PRIORITY JOURNAL; REVIEW; UNITED STATES; UTERINE CERVIX CANCER; VAGINA CANCER;

ADULT; CLINICAL COMPETENCE; FEMALE; HEALTH SURVEYS; HUMANS; INTERNET; KNOWLEDGE; LOGISTIC MODELS; MALE; MEDICINE; MIDDLE AGED; NEOPLASMS; PAPILLOMAVIRUS VACCINES; PHYSICIANS; UNITED STATES;

EID: 84856669111     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2011.3313     Document Type: Review

References (22)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527. (Pubitemid 36159887)
2. Cogliano V. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans: Human papillomavirus. Lyon: IARC, 2007.
3. Kjaer SK, Sigurdsson K, Iversen O, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2:868-878.
4. U.S. Food and Drug Administration. Gardasil. Rockville, MD: U.S. Department of Health & Human Services, updated August 5, 2011. Available at www.fda.gov/Biologics BloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm Accessed 2011.
5. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: A nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011;12:862-870.
6. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011 Oct 27;365: 1576-1585. PubMed PMID: 22029979.
7. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008;113(Suppl 10):2901-2909.
8. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:630-632.
9. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59: 626-629.
10. Morrow KM, Vargas S, Rosen RK, et al. The utility of non-proportional quota sampling for recruiting at-risk women for microbicide research. AIDS Behav 2007;11:586-595. (Pubitemid 46828776)
11. Cumming RG. Is probability sampling always better? A comparison of results from a quota and a probability sample survey. Community Health Stud 1990;14:132-137. (Pubitemid 20246693)
12. Im EO, Chee W. Quota sampling in internet research: Practical issues. Comput Inform Nurs 2011;29:381-385.
13. Brimmer DJ, Fridinger F, Lin JM, Reeves WC. U.S. healthcare providers' knowledge, attitudes, beliefs, and perceptions concerning chronic fatigue syndrome. BMC Fam Pract 2010;11:28.
14. Waltenburg R, Kobrynski L, Reyes M, Bowen S, Khoury MJ. Primary immunodeficiency diseases: Practice among primary care providers and awareness among the general public, United States, 2008. Genet Med 2010;12:792-800.
15. Irwin K, Montano D, Kasprzyk D, et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol 2006;108:397-409. (Pubitemid 44305683)
16. National and state vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR 2011;60:1117-1123.
17. United States Cancer Statistics: 1999-2007. Incidence and mortality web-based report, 2010. Accessed February 27, 2011.
18. Saraiya M. Burden of HPV-associated cancers in the United states. Presented at Advisory Committee on Immunization Practices, February 24, 2011.
19. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008;113(Suppl 10):2892-2900.
20. Watson M, Saraiya M, Wu X. Update of HPV-associated female genital cancers in the United States, 1999-2004. J Womens Health 2009;18:1731-1738.
21. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008;113(Suppl 10):3036-3046.
22. Dunne E, Markowitz L, Chesson H, Curtis R, Saraiya M, Unger E. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males-Advisory Committee on Immunization Practices (ACIP), 2011. December 23, 2011/Vol. 60/No. 50 p. 1705-1708.